Department of Obstetrics and Gynecology, Washington University School of Medicine, St Louis MO 63110, USA.
Center for Reproductive Health Sciences, Washington University School of Medicine, St Louis MO 63110, USA.
Hum Reprod. 2019 Jun 4;34(6):1106-1116. doi: 10.1093/humrep/dez041.
Does altering gut microbiota with antibiotic treatment have any impact on endometriosis progression?
Antibiotic therapy reduces endometriosis progression in mice, possibly by reducing specific gut bacteria.
Endometriosis, a chronic condition causing abdominal pain and infertility, afflicts up to 10% of women between the ages of 25 and 40, ~5 million women in the USA. Current treatment strategies, including hormone therapy and surgery, have significant side effects and do not prevent recurrences. We have little understanding of why some women develop endometriosis and others do not.
STUDY DESIGN, SIZE, DURATION: Mice were treated with broad-spectrum antibiotics or metronidazole, subjected to surgically-induced endometriosis and assayed after 21 days.
PARTICIPANTS/MATERIALS, SETTING, METHODS: The volumes and weights of endometriotic lesions and histological signatures were analysed. Proliferation and inflammation in lesions were assessed by counting cells that were positive for the proliferation marker Ki-67 and the macrophage marker Iba1, respectively. Differences in faecal bacterial composition were assessed in mice with and without endometriosis, and faecal microbiota transfer studies were performed.
In mice treated with broad-spectrum antibiotics (vancomycin, neomycin, metronidazole and ampicillin), endometriotic lesions were significantly smaller (~ 5-fold; P < 0.01) with fewer proliferating cells (P < 0.001) than those in mice treated with vehicle. Additionally, inflammatory responses, as measured by the macrophage marker Iba1 in lesions and IL-1β, TNF-α, IL-6 and TGF-β1 in peritoneal fluid, were significantly reduced in mice treated with broad-spectrum antibiotics (P < 0.05). In mice treated with metronidazole only, but not in those treated with neomycin, ectopic lesions were significantly (P < 0.001) smaller in volume than those from vehicle-treated mice. Finally, oral gavage of faeces from mice with endometriosis restored the endometriotic lesion growth and inflammation (P < 0.05 and P < 0.01, respectively) in metronidazole-treated mice.
LARGE-SCALE DATA: N/A.
LIMITATIONS, REASONS FOR CAUTION: These findings are from a mouse model of surgically-induced endometriosis. Further studies are needed to determine the mechanism by which gut bacteria promote inflammation, identify bacterial genera or species that promote disease progression and assess the translatability of these findings to humans.
Our findings suggest that gut bacteria promote endometriosis progression in mice. This finding if translated to humans, could aid in the development of improved diagnostic tools and personalised treatment strategies.
STUDY FUNDING AND COMPETING INTEREST(S): This work was funded, in part, by: a National Institutes of Health (NIH)/ National Institute of Child Health and Human Development (NICHD) grant (R00HD080742) to RK; Washington University School of Medicine start-up funds to RK; an Endometriosis Foundation of America Research Award to R.K.; and an NIH/NICHD grant (R01HD091218) to IUM. The authors report no conflict of interest.
抗生素治疗改变肠道微生物群对子宫内膜异位症进展有影响吗?
抗生素治疗可减少小鼠的子宫内膜异位症进展,可能是通过减少特定的肠道细菌。
子宫内膜异位症是一种导致腹痛和不孕的慢性疾病,影响 25 至 40 岁之间的女性多达 10%,美国约有 500 万女性受其影响。目前的治疗策略,包括激素治疗和手术,都有显著的副作用,并且不能预防复发。我们对为什么有些女性会患上子宫内膜异位症而有些女性不会患上这种病知之甚少。
研究设计、规模、持续时间:用广谱抗生素或甲硝唑治疗小鼠,然后进行手术诱导的子宫内膜异位症,并在 21 天后进行检测。
参与者/材料、设置、方法:分析了子宫内膜异位症病变的体积和重量以及组织学特征。通过分别计数增殖标志物 Ki-67 和巨噬细胞标志物 Iba1 阳性的细胞,评估病变中的增殖和炎症。评估有无子宫内膜异位症的小鼠粪便中细菌组成的差异,并进行粪便微生物转移研究。
在接受广谱抗生素(万古霉素、新霉素、甲硝唑和氨苄西林)治疗的小鼠中,子宫内膜异位症病变明显较小(~5 倍;P<0.01),增殖细胞较少(P<0.001)。此外,用广谱抗生素治疗的小鼠中,病变中的巨噬细胞标志物 Iba1 和腹腔液中的白细胞介素-1β、肿瘤坏死因子-α、白细胞介素-6 和转化生长因子-β1 等炎症反应均显著降低(P<0.05)。仅用甲硝唑治疗的小鼠,而不是用新霉素治疗的小鼠,异位病变的体积明显(P<0.001)小于用对照药物治疗的小鼠。最后,用患有子宫内膜异位症的小鼠的粪便进行口服灌胃,可恢复甲硝唑治疗小鼠的子宫内膜异位症病变生长和炎症(P<0.05 和 P<0.01)。
无。
局限性、谨慎的原因:这些发现来自于手术诱导的子宫内膜异位症的小鼠模型。需要进一步的研究来确定肠道细菌促进炎症的机制,确定促进疾病进展的细菌属或种,并评估这些发现在人类中的可转化性。
我们的研究结果表明,肠道细菌促进了小鼠的子宫内膜异位症进展。如果这一发现能在人类中得到证实,可能有助于开发更好的诊断工具和个性化治疗策略。
这项工作部分由美国国立卫生研究院(NIH)/儿童健康与人类发育国家研究所(NICHD)资助(R00HD080742)给 RK;华盛顿大学医学院启动资金给 RK;子宫内膜异位症基金会研究奖给 R.K.;以及 NIH/NICHD 拨款(R01HD091218)给 IUM。作者报告没有利益冲突。